Health related quality of life in patients with multiple myeloma undergoing a double transplantation
- 11 January 2005
- journal article
- Published by Wiley in European Journal of Haematology
- Vol. 74 (2) , 136-143
Abstract
Objectives: To investigate the subjective well-being of patients with newly diagnosed multiple myeloma who were treated in a tandem transplantation programme. Methods: Fifty-one patients participated in the prospective, longitudinal questionnaire study. The EORTC QLQ-C30 and the EuroQol-5D were administered 2 wk after completion of vincristine, adriamycin and dexamethason/vincristine, adriamycin and methyl prednison (VAD/VAMP) chemotherapy, both at hospital discharge after treatment with high-dose melphalan (HDM) and 1 month after this hospital discharge, at hospital admission, at the day of hospital discharge for peripheral stem cell transplantation (PSCT) and at 6 and 12 months following discharge after PSCT. Results: Overall, patients’ functioning improved during treatment and follow-up, with significant decreases shortly following PSCT. Shortly after HDM and PSCT, patients reported a considerable increase in levels of soreness in the mouth (+26/+36 points on a scale ranging form 0 to 100; P < 0.01), change of taste (+23/+21 points; P < 0.05/NS), nausea/vomiting (+26/+27 points; P < 0.01/< 0.05), appetite loss (+40/+43 points; P < 0.001) and diarrhoea (+25/+36 points; P < 0.01). However, none of these symptoms persisted during follow-up. Conclusion: The intensive treatment programme was subjectively being well tolerated by the majority of patients. The duration of declined quality of life after administration of HDM seemed to be short. The duration of subjective recovery after PSCT remained uncertain, but in any case was present at the 6 month follow-up. Together with the rather good results in survival, the evaluation of quality of life invites further exploration of double transplantations in multiple myeloma.Keywords
This publication has 25 references indexed in Scilit:
- Single versus Double Autologous Stem-Cell Transplantation for Multiple MyelomaNew England Journal of Medicine, 2003
- High-dose melphalan with G-CSF-stimulated whole blood rescue followed by stem cell harvesting and busulphan/cyclophosphamide with autologous stem cell transplantation in multiple myelomaBone Marrow Transplantation, 2001
- Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first‐line treatment in untreated multiple myelomaBritish Journal of Haematology, 1999
- Development of an EORTC questionnaire module to be used in health‐related quality‐of‐life assessment for patients with multiple myelomaBritish Journal of Haematology, 1999
- Health‐related quality of life assessed before and during chemotherapy predicts for survival in multiple myelomaBritish Journal of Haematology, 1997
- Measurement of health‐related quality of life in multiple myelomaBritish Journal of Haematology, 1996
- The Treatment of Multiple MyelomaNew England Journal of Medicine, 1994
- The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in OncologyJNCI: Journal of the National Cancer Institute, 1993
- EuroQol - a new facility for the measurement of health-related quality of lifeHealth Policy, 1990
- Melphalan/prednisone versus drug combinations for plasma cell myelomaEuropean Journal of Haematology, 1989